KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.

Pau Montesinos, Dylan M Marchione, Christian Recher, Michael Heuser, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Marta Riva, Rodrigo T Calado, Andre C Schuh, Su-Peng Yeh, Adriana E Tron, Jianan Hui, Diego A Gianolio, Sung Choe, Prapti Patel, Stéphane De Botton, Courtney D DiNardo, Hartmut Döhner

Blood Adv 9(20) 5177-5189

PMID40706052
PMCIDPMC12550153
DOI10.1182/bloodadvances.2025016399
发表日期2025-07-24
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

In the phase 3 AGILE study, after a 12.4-month median follow-up, ivosidenib, a mutant isocitrate dehydrogenase 1 (IDH1) inhibitor, combined with azacitidine significantly improved event-free survival, overall survival (OS), and complete remission rates compared with placebo-azacitidine in patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML), who were unfit for intensive chemotherapy. This post hoc analysis reports long-term follow-up results from AGILE after a median follow-up of 28.6 months. Overall, 148 patients were randomized to receive ivosidenib-azacitidine (n = 73) or placebo-azacitidine (n = 75). Median OS was significantly longer with ivosidenib (29.3 months; 95% confidence interval [CI], 13.2 to not reached) than with placebo (7.9 months; 95% CI, 4.1-11.3; hazard ratio, 0.42 [95% CI, 0.27-0.65]; P < .0001). Hematologic recovery was faster, more durable, and conversion to transfusion independence (53.8% vs 17.1%; P = .0004) was more common with ivosidenib than with placebo. Of 33 ivosidenib-treated patients evaluable for molecular measurable residual disease (MRD), 10 converted to MRD negativity. Although OS did not differ significantly between MRD-negative and MRD-positive responders at the 0.1% variant allele frequency (VAF) threshold, MRD-negative patients had numerically longer survival. MRD status appeared more predictive of long-term OS when an exploratory 1% VAF threshold was applied. MRD response was not associated with IDH1 variant, VAF, inferred clonality, or number of baseline comutations. The previously reported safety profile was maintained. These long-term efficacy and safety results confirm the benefit of ivosidenib-azacitidine in this challenging-to-treat population and support its use as a standard of care with the longest reported survival benefit for intensive chemotherapy-ineligible patients with IDH1-mutated AML. This trial was registered at www.ClinicalTrials.gov as #NCT03173248.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 1

OS_Median_follow-up_29.6_mo

OS

Figure 1 · Panel OS_Median_follow-up_29.6_mo

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel OS_Median_follow-up_29.6_mo 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 2 条曲线 2:extreme upward reversal曲线 3:off origin start曲线 3:extreme upward reversal
查看结果
NGS_MRD_0.1_VAF_IVO_AZA_10_33_30.3_MRD_1_

OS (MRD status)

Figure 1 · Panel NGS_MRD_0.1_VAF_IVO_AZA_10_33_30.3_MRD_1_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel NGS_MRD_0.1_VAF_IVO_AZA_10_33_30.3_MRD_1_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:very low support
查看结果
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Patient disposition in the ITT population.
非 KM Figure
Figure 2.OS in patients treated with ivosidenib + azacitidine or placebo + azacitidine in the ITT population. (A) Kaplan-Meier estimates of OS with a median follow-up of 28.6 months. (B) OS rates at 12, 24, and 36 months.
非 KM Figure
Figure 3.Hematology outcomes for patients treated with ivosidenib + azacitidine or placebo + azacitidine in the ITT population. Mean ± standard error hemoglobin (A), platelet counts (B), and neutrophil counts (C) over time. BL, baseline; C1D8, cycle 1 day 8.
非 KM Figure
Figure 4.Red blood cell and platelet transfusion independence in the ITT population. (A) Rate of conversion to red blood cell and platelet transfusion independence. (B) Maintenance of red blood cell and platelet transfusion independence from baseline.
非 KM Figure
Figure 5.OS in MRD-evaluable patients treated with ivosidenib + azacitidine according to MRD status (n = 33). (A) OS in MRD neg vs MRD pos patients. (B) OS in patients with MRD <1% vs patients with MRD ≥1% . NE, not evaluable.
非 KM Figure